Frontiers in Pharmacology (Aug 2020)

Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report

  • Carlos Spuch,
  • Marta López-García,
  • Tania Rivera-Baltanás,
  • Daniela Rodrígues-Amorím,
  • José M. Olivares,
  • José M. Olivares

DOI
https://doi.org/10.3389/fphar.2020.557629
Journal volume & issue
Vol. 11

Abstract

Read online

Lithium has shown the capacity to: a) inhibit the replication of several types of viruses, some of which are similar to the SARS-CoV-2 virus, b) increase the immune response by reducing lymphopenia, and c) reduce inflammation by preventing or reducing the cytokine storm. In the present study, we have treated six patients with severe COVID-19 infection with lithium carbonate. We found that lithium carbonate significantly reduced plasma reactive C-Protein levels, increased lymphocyte numbers and decreased the neutrophil-lymphocyte ratio, improving both inflammatory activity and the immune response in these patients. We propose that lithium carbonate may deserve a place in the treatment against COVID-19.

Keywords